Wedbush Reaffirms Outperform Rating for Kiniksa Pharmaceuticals International (NASDAQ:KNSA)

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report)'s stock had its "outperform" rating reissued by research analysts at Wedbush in a research report issued to clients and investors on Monday,RTT News reports. They presently have a $36.00 price objective on the stock. Wedbush's price objective would indicate a potential upside of 26.67% from the company's previous close.

KNSA has been the topic of a number of other research reports. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research report on Sunday, July 6th. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Finally, Wells Fargo & Company raised their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $39.67.

Kiniksa Pharmaceuticals International Trading Down 2.1%

KNSA stock traded down $0.60 during trading on Monday, hitting $28.42. The company had a trading volume of 492,519 shares, compared to its average volume of 559,497. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -113.68 and a beta of 0.05. The business has a 50 day moving average of $27.90 and a 200 day moving average of $23.50. Kiniksa Pharmaceuticals International has a fifty-two week low of $17.82 and a fifty-two week high of $30.69.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. The company had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The business's revenue for the quarter was up 72.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.25) EPS. As a group, equities analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Buying and Selling

In other news, insider Ross Moat sold 64,035 shares of the company's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $25.21, for a total value of $1,614,322.35. Following the completion of the transaction, the insider directly owned 9,415 shares in the company, valued at approximately $237,352.15. This represents a 87.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sanj K. Patel sold 62,116 shares of the business's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $27.33, for a total value of $1,697,630.28. Following the transaction, the chief executive officer owned 96,674 shares in the company, valued at approximately $2,642,100.42. This represents a 39.12% decrease in their position. The disclosure for this sale can be found here. Insiders sold 429,504 shares of company stock valued at $12,027,601 in the last 90 days. Corporate insiders own 53.48% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently bought and sold shares of the business. Nuveen LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter valued at approximately $16,992,000. Acadian Asset Management LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 170.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after acquiring an additional 651,700 shares in the last quarter. Braidwell LP boosted its stake in shares of Kiniksa Pharmaceuticals International by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after acquiring an additional 557,934 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Kiniksa Pharmaceuticals International by 149.1% during the 1st quarter. AQR Capital Management LLC now owns 491,761 shares of the company's stock worth $10,922,000 after purchasing an additional 294,319 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Kiniksa Pharmaceuticals International by 138.9% in the 4th quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock valued at $9,451,000 after acquiring an additional 277,827 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.